Geriatric factors can foretell tolerances to chemotherapy

March 14, 2013
Geriatric factors can foretell tolerances to chemotherapy
For elderly patients with metastatic colorectal cancer, scores on the Mini-Mental State Examination and Instrumental Activities of Daily Living were predictive of severe toxicity or unexpected hospitalization after fluorouracil-based chemotherapy with or without irinotecan, according to research published online March 4 in the Journal of Clinical Oncology.

(HealthDay)—For elderly patients with metastatic colorectal cancer (mCRC), scores on the Mini-Mental State Examination (MMSE) and Instrumental Activities of Daily Living (IADL) were predictive of severe toxicity or unexpected hospitalization after fluorouracil-based chemotherapy with or without irinotecan (IRI), according to research published online March 4 in the Journal of Clinical Oncology.

Thomas Aparicio, M.D., Ph.D., of the University of Paris, and colleagues conducted a study involving 123 elderly patients ranging in age from 75 to 91 years with mCRC to determine what geriatric factors predict chemotherapy feasibility.

The researchers found that in elderly patients with mCRC, factors that were significant predictors for grade 3 to 4 toxicity due to chemotherapy included IRI arm, MMSE less than or equal to 27/30, and impaired IADL. For elderly patients receiving a 33 percent reduced dose of chemotherapy, the predictors were alkaline phosphates above two times the upper limit of normal and IRI arm. For unexpected hospitalization, MMSE less than or equal to 27/30 and Geriatric Depression Scale less than or equal to two were significant predictors.

"In conclusion, our study is the first to prospectively demonstrate that geriatric characteristics are independent predictive factors of tolerance to chemotherapy and toxicity in mCRC," the authors write. " should be used with caution in patients who have cognitive impairment or dependency. Larger studies are needed to confirm our results."

Explore further: Full weight-Based chemo doses recommended for obese

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Full weight-Based chemo doses recommended for obese

April 6, 2012

(HealthDay) -- The American Society of Clinical Oncology Clinical Practice Guideline on Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer recommends using full weight-based cytotoxic chemotherapy doses ...

ASCO: Continuing avastin with 2nd-line chemo ups survival

June 5, 2012

(HealthDay) -- Continuing use of bevacizumab (Avastin) in combination with second-line chemotherapy improves overall survival (OS) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) who ...

Patient preference doesn't affect chemo in advanced CRC

September 21, 2012

(HealthDay)—For patients with metastatic colorectal cancer (mCRC), most patients are treated with chemotherapy, even if they express negative or marginal preferences, according to a study published online Sept. 12 in Cancer.

More intensive chemo ups survival in ewing sarcoma

October 29, 2012

(HealthDay)—More intensive chemotherapy (every two weeks versus every three weeks) improves event-free survival for patients with localized Ewing sarcoma, according to a study published online Oct. 22 in the Journal of ...

Recommended for you

Researchers thwart cancer cells by triggering 'virus alert'

August 27, 2015

Working with human cancer cell lines and mice, researchers at the Johns Hopkins Kimmel Cancer Center and elsewhere have found a way to trigger a type of immune system "virus alert" that may one day boost cancer patients' ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.